Last mentioned: Feb 26, 2026
Implementation
New list prices and Medicare negotiated rates take effect for Ozempic and Wegovy.
Negotiated Prices Effective
New Medicare-negotiated prices for selected drugs are scheduled to take effect.
Price Cut Announcement
Novo Nordisk officially announces 50% list price reductions for semaglutide products.
Price Cut Announcement
Novo Nordisk officially announces 50% list price reduction for 2027.
Senate Hearing
Novo Nordisk CEO Lars Fruergaard Jørgensen testifies before the Senate HELP Committee on high U.S. prices.
Senate Hearing
Novo Nordisk CEO Lars Fruergaard Jørgensen testifies before the Senate HELP Committee on drug pricing.
CMS Selection
Ozempic selected as one of the first 10 drugs for Medicare price negotiation.
Medicare Selection
Ozempic selected as one of the first 10 drugs for Medicare price negotiation.
Novo Nordisk has announced a landmark decision to reduce the list prices of its blockbuster GLP-1 medications, Ozempic and Wegovy, by up to 50%. The move follows intense regulatory scrutiny and the implementation of Medicare price negotiations under the Inflation Reduction Act.
Novo Nordisk has announced a major strategic shift by pledging to reduce the list prices of its blockbuster GLP-1 drugs, Ozempic and Wegovy, by up to 50% starting in 2027. This move follows intense regulatory pressure and the inclusion of Ozempic in Medicare's price negotiation program.